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Abstract: Zika virus (ZIKV; Flaviviridae) is a mosquito-borne flavivirus shown to cause fetal
abnormalities collectively known as congenital Zika syndrome and Guillain-Barré syndrome in recent
outbreaks. Currently, there is no specific treatment or vaccine available, and more effort is needed to
identify cellular factors in the viral life cycle. Here, we investigated interactors of ZIKV envelope
(E) protein by combining protein pull-down with mass spectrometry. We found that E interacts
with the endoplasmic reticulum (ER) resident chaperone, glucose regulated protein 78 (GRP78).
Although other flaviviruses are known to co-opt ER resident proteins, including GRP78, to enhance
viral infectivity, the role ER proteins play during the ZIKV life cycle is yet to be elucidated. We showed
that GRP78 levels increased during ZIKV infection and localised to sites coincident with ZIKV E
staining. Depletion of GRP78 using specific siRNAs significantly reduced reporter-virus luciferase
readings, viral protein synthesis, and viral titres. Additionally, GRP78 depletion reduced the ability of
ZIKV to disrupt host cell translation and altered the localisation of viral replication factories, though
there was no effect on viral RNA synthesis. In summary, we showed GRP78 is a vital host-factor
during ZIKV infection, which may be involved in the coordination of viral replication factories.
Keywords: Zika virus; proteomics; GRP78; virus–cell interactions
1. Introduction
Zika virus (ZIKV) is a mosquito-borne virus of the Flaviviridae family, which was originally
isolated from a Rhesus monkey in Uganda in 1947, and the first recorded human infection was
identified there in 1962–1963 [1,2]. ZIKV has since emerged as an important human pathogen during
the 2015–2016 outbreak across South and Central America [3]. ZIKV has been linked to severe
neurological and immunological diseases, including a pattern of birth and developmental defects
Viruses 2020, 12, 524; doi:10.3390/v12050524 www.mdpi.com/journal/viruses
Viruses 2020, 12, 524 2 of 19
known collectively as congenital Zika syndrome and Guillain-Barré syndrome [4–7]. Despite this,
there are currently no specific treatments for ZIKV infection available. As such, there is a pressing need
to delineate virus–host interactions more fully to understand the viral life cycle and enable targeted
approaches to therapy discovery [8,9].
ZIKV has a single-stranded, positive sense RNA genome approximately 11 kb in length, which is
translated into a single polyprotein [8]. Processing by host and viral proteases liberates both structural
(capsid (C), pre-membrane (prM), and envelope (E)) and non-structural proteins (NS1, NS2A, NS2B,
NS3, NS4A, NS4B, and NS5) [10]. As with other flaviviruses, ZIKV entry into host cells is initiated by
receptor-mediated endocytosis and is followed by trafficking through endosomes and the subsequent
release of the genome into the cytoplasm [11–13]. Replication is tightly linked to virus induced
re-modelling of the endoplasmic reticulum (ER) to form structures known as replication factories
(RF) [14]. Following translation, progeny virions assemble in the ER prior to maturation in the
trans-Golgi network and are subsequently exported from the cell [11,15]. Although some interactions
between ZIKV non-structural proteins as well as C with host cell proteins have been described [16–20],
knowledge about the functions/interactions of structural proteins during the viral life cycle is mostly
lacking. Recently, it was shown that E protein of dengue virus (DENV) interacts with heat shock
protein 90, with a decrease in the latter resulting in less cellular E protein and increased viral titres [21].
Other than this study, relatively little is known about intracellular interactors of E.
Structural analysis has revealed that 90 E dimers form an icosahedral scaffold that coats the
mature ZIKV particle, comparable to related flaviviruses such as DENV [22,23]. While the role E plays
in the life cycle as a whole has yet to be fully elucidated, it is known to be critical during viral entry
and assembly [12]. Differences in glycosylation of ZIKV E can modulate virus infectivity, as shown
in both mice and mosquito models. Lack of ZIKV E glycosylation reduced viremia in mice models,
as it is likely needed to aid binding to lectin-expressing cells; however, prevention of glycosylation
did not affect ZIKV neurovirulence. In addition, glycosylation was required for efficient transmission
to Aedes aegypti mosquitoes [24,25]. Following internalisation, pH changes in the endocytic pathway
induce structural changes in E that allow virus and host membrane fusion and genome release into the
cytoplasm [15]. Subsequent interactions between the host cell and ZIKV E are not well understood.
Here, we aimed to identify cellular protein interactors of ZIKV E during the viral life cycle to
increase our understanding of E roles and functions during the viral life cycle. For this, we used a
mass-spectrometry based proteomics approach, which we believed would give us the best overview of
cellular proteins that interact with E and allow us to investigate the role and the relevance of some
of those interactions further. From the data obtained, we identified an interaction between E and
glucose-regulated protein 78 kDa (GRP78)—an essential protein for mediating the unfolded protein
response (UPR) as well as an important ER-resident chaperone [26–28]. UPR proteins, including
GRP78, may be important during ZIKV infection. Activation of this pathway has been linked to clinical
features of ZIKV infection such as microcephaly [29]. Additionally, ZIKV has been shown to upregulate
the production of UPR proteins, including GRP78, during infection of neural cell culture [30]. In this
study, GRP78 was found to re-localise to sites of ZIKV E staining, and GRP78 expression was seen to
increase after a 24 h infection. While chemical modulators of GRP78-mediated ER stress responses
did not affect ZIKV replication, GRP78 depletion significantly reduced the production of infectious
virus particles. Further experiments revealed that GRP78 is important for ZIKV replication post-entry
but prior to maturation and egress. Depletion of GRP78 reduced viral protein synthesis but not viral
RNA synthesis, and GRP78 is required for maintaining the ER localisation of viral RFs. This suggests a
novel and important role for GRP78 in the ZIKV life cycle.
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2. Materials and Methods
2.1. Virus Strains
ZIKV/H. sapiens/Brazil/PE243/2015 (abbreviated to ZIKV PE243) used in the study was characterised
and is available from the authors [31]. ZIKV PE243 was obtained from collaborators at passage 2, and a
passage 3 working stock was expanded from this. The generation of a ZIKV nanoluciferase-expressing
reporter virus in Vero E6 cells, here termed ZIKV-Nanoluc, has been described previously [32,33].
2.2. Cells
Human A549 (ECACC, UK, 86012804) and African green monkey Vero E6 (ATCC, Manassas, VA,
USA, CCL-81™) cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM, Thermo Fisher
Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS). A549 cells expressing
bovine viral diarrhea virus (BVDV) N-terminal protease (NPro), abbreviated A549-NPro cells (kindly
provided by R. E. Randall, University of St Andrews, St. Andrews, UK), were maintained as described
as above but with the addition of 2 µg/mL blasticidin to select for cells expressing BVDV-NPro [34].
BVDV NPro has been shown to inhibit IRF3 signalling and therefore reduce type 1 interferon induction.
These cells were used for amplifying ZIKV stocks and performing plaque assays where indicated [34].
All cell lines were incubated in a humidified 5% CO2 incubator at 37 ◦C. All live cell-culture work was
conducted in biosafety cabinets.
2.3. Virus Growth and Titration
Vero E6 cells were used to rescue ZIKV Nanoluc as previously described [33]. A549-NPro cells
were infected with ZIKV PE243 or ZIKV-Nanoluc, and the supernatant was harvested following
the observation of cytopathic effects (CPE) 5–7 days later. Supernatants were serially diluted onto
A549-NPro cells and overlaid with DMEM supplemented with 2% FBS and 1.2% Avicel (FMC
BioPolymer, Philadelphia, PA, USA) for 5 days at 37 ◦C. Cell monolayers were fixed with 4%
formaldehyde for 20 min prior to staining with toluidine blue (Sigma-Aldrich, St. Louis, MO, USA) to
visualise plaque formation. All infections were performed in DMEM supplemented with 2% FBS at
37 ◦C with 5% CO2.
2.4. Small Molecule Inhibitor Assays
Epigallocatechin-gallate (EGCG, Sigma-Aldrich, St. Louis, MO, USA, E4143) and honokiol
(HNK, Sigma-Aldrich, St. Louis, MO, USA, H4914) were dissolved in DMSO at 100 mM and 10 mM,
respectively, and stored at −20 ◦C. To determine cell viability, EGCG and HNK were serially diluted
onto 1 × 104 A549 cells for 26 h. CellTitre-Glo Luminescent Cell Viability Assay (Promega, Madison, WI,
USA) reagent was then added to cells following manufacturer’s instructions. Values were normalised
to DMSO controls. For infection assays, A549 cells were treated with EGCG or HNK 2 h prior to and/or
throughout a 24 h infection with ZIKV-Nanoluc (multiplicity of infection (MOI) 0.1). Where specified,
ZIKV-Nanoluc was incubated with either EGCG or DMSO for 2 h in DMEM plus 2% FBS prior to
infection of cells. To measure activity of Nanoluc expressed by a virus, cells were first lysed in Passive
Lysis Buffer (Promega, Madison, WI, USA) before detection with Nano-Glo Luciferase Assay System
plate reader (Promega, Madison, WI, USA). Values were normalised to infected cells treated with
DMSO only. All drug treatments were performed in DMEM supplemented with 2% FBS at 37 ◦C with
5% CO2.
2.5. Transfection of Nucleic Acids and Silencing of Gene Expression
To knockdown GRP78 expression, A549 cells were seeded in 24-well plates at a density of 1 × 105
cells per well before transfection of homogenous siRNA molecules targeting GRP78 (siG, Thermo
Fisher Scientific, Waltham, MA, USA, s6980; siG #2, s6981). As a negative control, Neg control siRNA 2
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(siN, Thermo Fisher Scientific, Waltham, MA, USA, 4390846) was used. When transfecting, 5 pmol of
siRNA was used with 2 µL of DharmaFECT 2 (Horizon Discovery, Cambridge, UK) per well according
to the manufacturer’s protocol.
2.6. Freeze/Thaw Assay
A549 cells were treated with siN or siG and then infected with ZIKV PE243 at MOI 5 for 24 h.
Supernatant was harvested from siN and siG cells and split into two fractions. The first fraction was
serially diluted and titred on A549-NPro cells. The second was subject to 3× freeze/thaw (f/t) cycles,
whereby supernatants were frozen on dry ice for 5 min and thawed at 37 ◦C for 2 min and titred on
A549-NPros. Cell monolayers from corresponding cell supernatants were then washed with 1× trypsin
and with 3× PBS washes to remove residual virus particles. These cells were subject to 3× f/t cycles,
and cellular debris was pelleted at 4000× g for 10 min and clarified supernatant serially diluted onto
A549-NPros to calculate titre.
2.7. Dual Luciferase Assay
A549 cells were treated with siN or siG for 72 h. Cells were infected with ZIKV-Nanoluc (MOI 5)
for 48 h. For the final 24 h of infection, 100 ng of the firefly luciferase plasmid expression pGL4.13
(Promega, Madison, WI, USA) was transfected into cells using LT-1 Transfection Reagent (Mirus Bio,
Madison, WI, USA) following manufacturers’ instructions. The Firefly luciferase gene in pGL4.13
is under the control of a cytomegalovirus (CMV) promoter, and its expression was used as a proxy
for host-controlled translation. Cells were harvested and luciferase values were measured using
the Nano-Glo Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA) following the
manufacturers protocol.
2.8. Protein Immunoprecipitation (IP)
At 24 h post-infection (hpi), cells were scraped and washed with PBS before resuspension in lysis
buffer (150 mM NaCl, 5 mM MgCl2, 20 mM HEPES (pH 7.4), 0.5% Triton X-100, 1:100 Halt protease
inhibitor cocktail (Thermo Fisher Scientific, Waltham, MA, USA)). After lysis, 1/50 of sample was taken
for immunoblot analysis and mixed with 4X Bolt LDS Sample Buffer (final 1× in H2O, Thermo Fisher
Scientific, Waltham, MA, USA) and 10× Bolt Sample Reducing Agent (final 1× in H2O, Thermo Fisher
Scientific, Waltham, MA, USA). Immunoprecipitation samples were kept on ice for 20 min, followed
by centrifugation at 15,000× g at 4 ◦C for 20 min. The supernatant was transferred into fresh tubes on
ice and incubated with mouse anti-ZIKV E antibody (Aalto Bio Reagents, Dublin, Republic of Ireland,
AZ 1176) or rabbit anti-GRP78 antibody (Abcam, Cambridge, UK, ab21685) for 2 h at 4 ◦C. Following
this, protein G magnetic beads (Dynabead Protein G, Thermo Fisher Scientific, Waltham, MA, USA)
equilibrated with cold washing buffer (150 mM NaCl, 5 mM MgCl2, 20 mM HEPES (pH 7.4), 0.5%
Triton X-100) were added for 1 h at 4 ◦C before 4×washes with cold washing buffer. Beads were finally
re-suspended in sample buffer (1 Bolt LDS Sample Buffer, 1× Bolt Sample Reducing Agent in H2O)
and subjected to proteomic analysis and/or Western blot. Before proteomic analysis, proteins were
first digested with trypsin using the filter aided sample preparation (FASP) protocol as previously
described [35].
2.9. Peptide Analysis by LC-MS/MS
Peptides were solubilised in 1% acetonitrile (ACN) (Rathburn Chemicals, Walkerburn, UK) with
0.05% formic acid (FA) (Sigma-Aldrich, St. Louis, MO, USA) and separated using an UltiMate 3000
RSLCnano liquid chromatography system (Thermo Fisher Scientific, Waltham, MA, USA) prior to
online analysis by electrospray ionisation (ESI) mass spectrometry on an LTQ-Orbitrap Elite mass
spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). Peptide samples were desalted and
concentrated for 4 min on a C18 trap column (5 mM × 300 µM ID, 5 µM, 100 Å) (Thermo Fisher
Scientific, Waltham, MA, USA), washed for 7 min with 1% ACN with 0.05% FA at a flow rate of
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25 µL/min, then separated through an Acclaim PepMap 100 C18 Column (150 mm × 75 µm ID, 3 µm,
100 Å) (Thermo Fisher Scientific, Waltham, MA, USA). The gradient, at a flow rate of 300 nL/min, was
4–40% of 80% ACN in 0.08% FA over 90 min, then 40–100% of 80% ACN in 0.08% FA over 14 min,
held at 100% for 5 min, and then re-equilibrated to 4% of 80% ACN in 0.08% FA for a total of 125 min.
Peptide ions were detected in the Orbitrap mass spectrometer with a precursor scan at 60,000 resolving
power within the mass range of m/z 400–2000. Tandem mass spectrometry (MS/MS) was performed on
the 20 most intense ions detected in each precursor scan, with singly-charged ions being excluded
from the selection. MS/MS by collision-induced dissociation (CID) was carried out and detected in the
linear ion trap (LTQ). A dynamic exclusion of 180 s was used to prevent repeated analyses of high
intensity ions at the expense of lower intensity ions.
2.10. Data Analysis
Raw data were analysed by Proteome Discoverer (v.2.1.1.21, Thermo Fisher Scientific, Waltham,
MA, USA). Protein identification was performed against ZIKV PE243 in the UniProt/SwissProt database.
Carbamidomethyl (C) was set as a fixed modification, while Oxidation (M) was set as a variable
modification. The precursor and the fragment mass tolerances were set to 10 ppm and 0.6 Da,
respectively, with up to 2 missed cleavages allowed. The false discovery rate (FDR) was 0.01.
2.11. Immunoblot Analysis
Proteins were separated on Bolt 4–12% Bis-Tris Plus gels (Thermo Fisher Scientific, Waltham,
MA, USA) and transferred to Protran 0.45 NC membranes (GE Healthcare Life Sciences, Chicago, IL,
USA) using the Trans-Blot SD semi-dry transfer cell. The membrane was blocked for 1 h in 5% w/v
non-fat dry milk in 0.1% Tween-PBS. The membrane was then incubated overnight at 4 ◦C in 5% w/v
non-fat dry milk in Tween-PBS containing either mouse anti-E (Aalto Bio Reagents, Dublin, Republic of
Ireland, AZ 1176), rabbit anti-actin (Sigma-Aldrich, St. Louis, MO, USA, A2066), rabbit anti-NS5 [33],
rabbit anti-gamma tubulin (Sigma-Aldrich, St. Louis, MO, USA, T3559), or rabbit anti-GRP78 (Abcam,
Cambridge, UK, ab21685). Following 3 × 10 min washes with Tween-PBS, the membranes were
then incubated for 1 h in 5% w/v non-fat dry milk in Tween-PBS with anti-mouse or anti-rabbit
secondary antibody conjugated with either horseradish peroxidase (HRP) (Abcam, Cambridge, UK) or
a near-infrared fluorescent dye (LI-COR Biosciences, Lincoln, NE, USA). This was followed by three
10 min washes with 0.1% Tween-PBS buffer; enhanced chemi-luminescence reagent (Thermo Fisher
Scientific, Waltham, MA, USA) was used for signal detection of HRP antibodies, whereas fluorescently
labelled antibodies were imaged on an Odyssey CLx (LI-COR Biosciences, Lincoln, NE, USA).
2.12. Immunofluorescence Microscopy
A549 cells were seeded at a density of 5 × 104 cells per well onto 13 mm coverslips and allowed to
settle overnight. Cells were infected with ZIKV PE243 (MOI 1) for indicated durations and fixed with
4% formaldehyde for 20 min at room temperature. Cells were then permeabilised with 0.5% Triton
X-100 in PBS for 10 min and blocked with 5% FBS in PBS for 1 h. Antibodies targeting ZIKV E (mouse)
or GRP78 (rabbit) or dsRNA (mouse, J2, Scicons, Budapest, Hungary) were diluted 1:1000 in 5% FBS in
PBS and incubated with cells for 2 h at room temperature. Following this, staining with AlexaFluor
secondary antibodies (Thermo Fisher Scientific, Waltham, MA, USA) diluted 1:1000 in 5% FBS in PBS
was done for 1 h. Coverslips were mounted onto microscope slides using HardSet Antifade Mounting
Medium with 4′,6-diamidino-2-phenylindole (DAPI) (VectorLaboratories, Burlingame, CA, USA).
Images were taken on a Zeiss LSM 710 inverted confocal microscope (Carl Zeiss, Jena, Germany).
2.13. cDNA Synthesis and RT-qPCR
Trizol (Thermo Fisher Scientific, Waltham, MA, USA) was added to 2 × 105 A549 cells per well
in a 24-well plate with triplicate wells pooled to isolate total RNA and purified according to the
manufacturer’s instructions. For cDNA synthesis, 1 µg RNA was used as template for Superscript III
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reverse transcriptase (Thermo Fisher Scientific, Waltham, MA, USA) with random primers (Promega,
Madison, WI, USA). Quantitative RT-PCR for ZIKV and the housekeeping gene, GAPDH, was
performed using specific primers (ZIKV: Fwd: GTTGTCGCTGCTGAAATGGA Rev: GGGGACTCTG
ATTGGCTGTAGAPDH: Fwd: GGTGGTCCAGGGTTTCTTA Rev: GTTGTCTCCTGCGACTTCA).
Signal was detected using SYBR green Mastermix (Thermo Fisher Scientific, Waltham, MA, USA) and
an ABI7500 Fast qPCR machine according to manufacturer’s protocol. Results were analysed using the
∆∆Ct method [36].
2.14. Statistical Analysis
Data were visualised and analysed in GraphPad Prism v.9 (San Diego, CA, USA). Statistical
significance was assessed using two-tailed unpaired Student’s t-test with Welch’s correction.
2.15. Data Availability
Data used to compile all figures found in this paper can be located here: http://dx.doi.org/10.5525/
gla.researchdata.959.
3. Results
3.1. ZIKV E Interacts with GRP78
To identify interactors of ZIKV E, A549 cells were mock-treated or infected with ZIKV PE243 before
cells were harvested, lysed, and immunoprecipitated using a ZIKV E-specific antibody. Samples were
subjected to proteomic analysis, and multiple putative protein partners were identified (Table 1).
A protein was considered a potential interactor if it was absent in at least two of the control samples
but present in at least two replicates from infected cells. A full list of identified proteins is recorded in
Supplementary Table S1. Proteins identified included glucose-regulated protein 78 kDa (GRP78, also
known as HSPA5 or BiP), an ER-resident protein chaperone involved with coordinating cellular stress
responses [27,37]. As GRP78 has been shown to be important in a range of other viruses, including
other flaviviruses, it was chosen for further investigation here [38–40].
Table 1. Potential interactors of Zika virus (ZIKV) envelope (E) identified by proteomic analysis.
Protein UniProtAccession
Infection,
Sample 1
Infection,
Sample 2
Infection,
Sample 3
Control,
Sample 4
Control,
Sample 5
Control,
Sample 6
LMNA P02545 Yes Yes Yes No Yes No
PGAM5 Q96HS1 Yes Yes No Yes No No
GRP78 P11021 Yes Yes Yes No No No
OASL Q15646 Yes Yes No No No No
TAO1 Q7L7X3 Yes Yes Yes No No No
The interaction between GRP78 and ZIKV E was confirmed by co-IP with a ZIKV E-specific
antibody. Cell lysates were analysed for GRP78, E, and tubulin expression (Figure 1a); the same lysates
were subjected to IP using an anti-E antibody, and samples were probed for GRP78 and E (Figure 1b).
GRP78 and E were also shown to co-localise using immunofluorescence staining. In mock-infected
A549 cells, GRP78 displays a diffuse localisation (Figure 1c). However, following infection, GRP78 was
seen to localise to a perinuclear location coincident with sites of E staining (Figure 1d). To investigate
the expression of GRP78 following infection, lysates of mock or ZIKV PE243 infected A549 cells
were harvested and analysed via Western blot for GPR78; a representative blot is shown (Figure 1e).
Densitometry of triplicate Western blots revealed a significant increase of GRP78 levels relative to an
actin loading control (Figure 1f), if cells infected at MOI of 5.
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3.2. Small Molecule Inhibitors of GRP78-Mediated UPR do not Affect Viral Replication
Under non-stress condition , GRP78 binds to and inactivates ATF6, IRE1, and PERK, three effector
proteins of the UPR [41]. When exposed to stress stimuli, GRP78 undergoes a conformational change,
leading to the release of effector proteins and activation of the UPR [42,43]. These effector proteins
have myriad functions within the cell that aim to restore protein homeostasis or induce cell death
if this is not possible [44]. Upon release from GRP78, PERK can phosphorylate the α subunit of the
eIF2, leading to translational arrest, while IRE1 and ATF6 induce transcriptional upregulation of
UPR members, resulting in a positive feedback loop [45–47]. The activity of the UPR can be blocked
through the use of small molecule inhibitors such as (honokiol) HNK and (epigallocatechin-gallate)
EGCG [48]. To test whether GRP78-coordinated stress responses impact ZIKV replication, A549 cells
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were treated with known inhibitors of GRP78, HNK (Figure 2a), or EGCG (Figure 2b) at indicated
concentrations prior to and throughout infection with ZIKV-Nanoluc. The viability of cells in the
presence of drugs alone was also plotted. HNK treatment had no effect on cell survival or Nanoluc
readings at any concentration tested. In contrast, EGCG significantly reduced Nanoluc readings while
having no effect on cell survival at 10 µM. To investigate this further, 10 µM EGCG was added to A549
cells at time points during or after ZIKV-Nanoluc infection and subsequently maintained throughout
infection until cells were lysed and Nanoluc activity was observed (Figure 2c). Only when EGCG was
in the supernatant at the time of infection was a reduction in Nanoluc readings observed. To establish
whether GRP78 inhibition affected early stages of ZIKV infection or whether EGCG directly inhibited
ZIKV binding to cells, ZIKV-Nanoluc was incubated with EGCG or a DMSO vehicle control prior
to infection. When ZIKV-Nanoluc was incubated with EGCG before infection, Nanoluc readings
were reduced regardless of whether cells had been pre-treated with EGCG or not (Figure 2d). In all
cases, ZIKV Nanoluc readings were only reduced when EGCG encountered ZIKV in the inoculum,
indicating EGCG could potentially act directly on virions by either inhibiting viral binding to the cell
or through direct damage to viral particles. These data corroborate other results suggesting that EGCG
can prevent viral fusion by binding to ZIKV E protein [49,50]. Together, these data show that inhibition
of GRP78 using HNK and EGCG does not affect ZIKV infection in A549 cells.
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Figure 2. EGCG inhibits ZIKV independent of GRP78. A549 cells were treated with either (a) honokiol
(HNK) or (b) epigallocatechin-gallate (EGCG) at indicated concentrations for 26 h. Cell viability was
measured relative to a DMSO control as indicated by the li e graph. Separately, A549 cells were treated
with the same drug once tr tions for 2 h prior to infection with ZIKV-Nanoluc (MOI 0.1) for 24 h.
Nanoluc readings are relative to a DMSO control indicated by the bar graph. (c) EGCG (10 µM) was
added to A549 cells and maintained throughout a 24 h ZIKV-Nanoluc infection or added 1 h or 4 h
post-removal of virus inoculum. Nanoluc values were measured relative to a DMSO vehicle control.
(d) ZIKV-Nanoluc was incubated with either DMSO or EGCG (10 µM) independently of cells for 2 h at
37 ◦C. Simultaneously, A549 cells were treated with DMSO or EGCG for 2 h before the drug containing
media was replaced with drug treated or DMSO treated control virus for 1 h. Following this, virus
inoculum was removed and replaced with DMEM containing either DMSO or EGCG as before for a
further 23 h. Error bars represent the standard error of the mean of triplicate repeats. An unpaired
Student’s t-test with Welch’s correction was used to determine statistical significance where n.s = not
significant, * p-value < 0.05, ** p-value < 0.01 and *** p-value < 0.001. (a–d) n = 3.
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3.3. GRP78 Depletion Reduces ZIKV Infectious Titre
Although inhibition of GRP78 mediated UPR responses appeared to have no effect on ZIKV
replication, the importance of GRP78 itself during ZIKV infection was tested using GRP78-specific
siRNA. GRP78 knockdown efficiency was assessed by comparing relative densitometry of GRP78
protein expression following siRNA treatment (siG) vs. control siRNA (siN). Western blots of cell
lysates (Figure 3a) showed that siG treatment significantly decreased GRP78 expression compared to
siN (Figure 3b). GRP78 knockdown cells were infected with ZIKV PE243, and total cellular RNA was
isolated at regular intervals, while cell supernatant was harvested after 24 h. qPCR was performed on
extracted RNA, and the fold change expression of viral RNA relative to a GAPDH control was calculated
(Figure 3c). Cell supernatants were serially diluted onto A549-NPro cells, and plaque formation was
determined (Figure 3d). GRP78 depletion did not appear to impact viral RNA production but did
significantly reduce viral titres by ~7.5 fold.
To confirm the findings of siG, we tested another siRNA against GRP78 (siG #2), which similarly
reduced GPR78 expression. Both siG and siG #2 reduced luciferase signal detection from ZIKV-Nanoluc
infected cells (Figure S1). These data imply that GRP78 is important for ZIKV infection at a step
downstream of genome replication. To further investigate whether viral entry to the cell is affected
by GRP78 depletion, we probed for GRP78 protein expression on the cell surface. A549 cells appear
to have low surface GRP78 expression compared to intracellular levels, and there was no significant
change in ZIKV RNA levels following a high MOI infection in siN or siG treated cells (Figure S2).
As GRP78 depletion reduced ZIKV infectious particle release, and as GRP78 has been shown
to be able to facilitate the egress and the trafficking of human cytomegalovirus, the possibility of
an accumulation of intracellular ZIKV particles was investigated [40]. Intracellular viral particles
were released from cells using multiple freeze/thaw (f/t) cycles as has been described previously [51].
To investigate this, A549 cells were treated with siN or siG and then infected with ZIKV PE243.
Cell supernatants were harvested, split into two equal fractions, and titred by plaque assay. The first
fraction compared viral titre between GRP78 depleted and control cells (Figure 3e, siN S vs. siG
S), while the second fraction underwent 3× f/t cycles to control for the effect of f/t on viral titre
(Figure 3e, f/t siN S vs. f/t siG S). Triplicate f/t cycles consistently reduced supernatant titre by ~5-fold.
Subsequently, remaining cell monolayers were then washed to remove residual virus and subjected
to 3× f/t cycles to liberate intracellular virus (Figure 3e, siN C vs. siG C). Importantly, there was
no significant difference between the fold-reduction of supernatant (Figure 3f, siN vs. siG S) and
intracellular (Figure 3f, siN vs. siG C) virus titres following siG treatment, indicating there was no
accumulation of intracellular, infectious virions (Figure 3f). This suggested that GRP78 depletion does
not block the export of infectious virus particles out of the cell and that the defect in virus production
was before ZIKV egress.
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to actin levels to measure protein expression. (c) Cells treated with siRNA were infected with ZIKV
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24 h. Supernatant was harvested from siN and siG cells, and the titre was calculated for untreated
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(labelled siN C and siG C). (f) The reduction in titre between siN treated cells and siG shown in (e)
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3.4. GRP78 Knockdown Specifically Impacts Viral Translation
The previous results suggested that GRP78 was important during the ZIKV life cycle post-
replication but pre-egress. To investigate whether viral protein translation and/or assembly were
impacted by GRP78 depletion, A549 cells were treated with siRNA before infection with ZIKV-Nanoluc.
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Cells were lysed, and Nanoluc readings were measured (Figure 4a). At all time-points measured, there
was a significant reduction in Nanoluc activity in siG treated cells. Additionally, translation of two
ZIKV proteins, E and NS5, was found to be decreased in GRP78 depleted cells as measured by Western
blot (Figure 4b). These results taken together with the data displayed in Figure 3 imply that GRP78 is
required for viral protein translation.
Following this, we aimed to determine whether this decrease in viral protein production was
because of a specific reduction in virus translation or a host-wide translation shut down. A549 cells
were treated with siRNA and transfected with a pGL4.13 Firefly luciferase (FLuc) reporter plasmid
to measure host translation in the presence or the absence of ZIKV-Nanoluc infection. Cells were
lysed, and FLuc and Nanoluc readings were measured. Nanoluc readings were normalised to siN
treated cells that had only been infected (I) (Figure 4c), while FLuc readings were normalised to siN
treated cells that had only been transfected (T) (Figure 4d). As before, GRP78 knockdown significantly
reduced Nanoluc readings (Figure 4c, siN I vs. siG I), while depletion of GRP78 in uninfected cells
did not reduce FLuc production (Figure 4d siN T vs. siG T). This indicated that the reduction in
ZIKV protein synthesis following GRP78 knockdown is specific to ZIKV protein production alone.
Additionally, FLuc readings in siN treated and infected cells were significantly reduced, suggesting
that ZIKV infection was hijacking or disrupting host translation machinery (Figure 4d, siN T vs. siN
T+I). Surprisingly, ZIKV infection in siG treated cells did not reduce FLuc levels (Figure 4d, siG T
vs. siG T+I), which suggests that GRP78 could be necessary to efficiently hijack cellular translational
machinery, and this may be the mechanism by which GRP78 influences infection.
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Figure 4. GRP78 depletion r duc s ZIKV translat . A549 cells were treated with siN or siG for 72 h.
(a) Cells were infected with ZIKV-Nanoluc at a MOI 0.1 before cells were lysed and Nanoluc levels were
measured at 16, 24, or 48 hpi and normalised to each timepoint separately. (b) A549 cells were infected
with ZIKV PE243 at MOI 10 for 24 h following siRNA treatment. A representative blot of triplicate
experiments is shown detecting ZIKV NS5 and E with actin as loading control. (c,d) Following siRNA
treatment, cells were either transfected with 100 ng of pGL4.13 FLuc expressing plasmid (labelled ‘T’),
infected with Nanoluc at MOI 5 (labelled ‘I’) or both (labelled ‘T+I’). Cells were lysed, and (c) Nanoluc
readings or (d) FLuc readings were measured. ZIKV-Nanoluc readings are relative to siN ‘I’, while
FLuc readings are normalised to siN ‘T’. Experiments were performed in triplicate, and the mean and
the standard error of the mean are plotted. An unpaired Student’s t-test with Welch’s correction was
used to determine statistical significance where n.s = not significant, * p-value < 0.05, ** p-value < 0.01.
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3.5. Viral dsRNA Localisation is Disrupted Following GRP78 Depletion
To further explore whether GRP78 has a role in coordinating viral translation, the localisation of
ZIKV double-stranded RNA (dsRNA) was investigated. dsRNA is an intermediate product of ZIKV
replicative cycle and localises to RFs. These are hubs of viral replication and translation located on
the ER [14,52]. A549 cells were treated with siN or siG and infected with ZIKV PE243. GRP78 and
ZIKV dsRNA were then stained with specific antibodies (Figure 5). Mock infected cells showed no
staining for dsRNA; however, in siN treated cells infected with ZIKV PE243, dsRNA clustered tightly
to the perinuclear sites to which GRP78 re-localises during infection. As expected, treatment with
siG significantly reduced GRP78 signal consistent with Western blot analysis (Figure 3a). In GRP78
depleted cells, dsRNA signal was diffuse throughout the cytoplasm in stark contrast to the highly
localised staining seen in control cells.
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Figure 5. Viral dsRNA localisation is altered following GRP78 depletion. A549 cells were treated with
siN or siG and mock infected or infected with ZIKV PE243 at MOI 0.1 for 24 h. Cells were stained with
an anti-dsRNA a ti ( ite) and an anti-GRP78 antibody (green), and the nuclei were stained with
DAPI (blue). Images were taken on an LSM 710 conf cal microsc pe. Scale bars repr sent 10 µm, and
images are rep sentative of triplicate exp riments.
4. Discussion
The emergence of ZIKV in the Americas highlighted the need for research to develop specific
vaccines and therapeutics. In addition to viral proteins, host factors should be considered as candidates
for treatments. Here, we analysed protein interactors of ZIKV E protein in human A549 cells and
identified GRP78, a well-known ER-resident chaperone as a binding partner [53]. This interaction was
verified by co-immunoprecipitation, and the co-localisation of E and GRP78 in cells was confirmed
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using confocal microscopy. Whether this interaction is direct or is mediated through other cellular or
viral proteins has yet to be determined. It is possible active viral remodelling of cellular ER structures
could result in proximity between GRP78 and E, giving rise to the observed interaction [14,54,55].
Another protein interactor of ZIKV E was 2′,5′-Oligoadenylate synthetase-like (OASL), an interferon
stimulated gene that has been shown to be anti-viral against hepatitis C virus and has also been
implicated in the response to ZIKV infection in placentas [56–58]. Information linking other protein
interactors of ZIKV E identified in this study to other viruses is lacking; however, they may represent
interesting targets for future studies.
Knockdown of GRP78 with specific siRNAs in A549 cells revealed it has a pro-viral role in ZIKV
infection. GRP78 has previously been shown to enhance replication of other related flaviviruses.
For example, GRP78 was reported to interact with Japanese encephalitis virus (JEV) E protein domain
III and is an important factor facilitating virus entry into mouse neuronal cells, mouse primary neurons,
and human hepatoma Huh7 cells [38]. Similarly, GRP78 is important for duck Tembusu virus entry [59].
Data regarding the role of GRP78 during DENV replication remains inconclusive. For DENV 2, it was
found that GRP78 acts as an entry co-receptor in human liver HepG2 cells [60]. However, another
study in HEK 293T cells concluded that GRP78 had no role in virus entry, although it was important
during viral antigen production [39]. Similar to JEV, GRP78 interacted with DENV via domain III of
DENV E protein [61]. The domain of ZIKV E that interacts with GRP78 has not yet been identified;
however, it is possible they interact via domain III as seen for other flaviviruses. These data highlight
that, while GRP78 seems to be a common co-factor for flaviviruses, the mechanism of action of GRP78
can be diverse.
To further characterise the pro-viral role of GRP78, we initially focused on the early stages of
infection. GRP78 did not seem to be expressed at high levels on the surface of A549 cells, and GRP78
knockdown did not reduce incoming ZIKV copy number as measured by qPCR. Furthermore, GRP78
knockdown had no effect on viral RNA production over a time course of infection, together indicating
that there was no defect in viral entry or replication. However, there was a significant reduction in
the release of infectious viral particles. These results are in line with a previous study conducted
with DENV, where depletion of GRP78 resulted in 100-fold reduction in virion production, but there
was no effect on viral RNA synthesis [39]. Further experiments revealed that there was no defect
in virus egress as a result of GRP78 knockdown cells and that ZIKV protein synthesis was reduced.
Taken together, these data can explain the diminished production of new infectious virions, though
we cannot exclude other explanations for this phenotype, including disruption of viral cap synthesis
or protein processing and maturation. Interestingly, while viral protein synthesis was reduced, RNA
synthesis was not affected. This could be explained by the fact that viral non-structural proteins have
other roles aside from viral RNA replication, as shown by DENV and ZIKV NS5, the majority of which
are located in the nucleus and not in RFs [62,63].
Reduced viral protein synthesis could have been linked to translational inhibition via the induction
of ER stress. GRP78 is a well-known sensor of the UPR [53]. In non-stress conditions, GRP78 is bound
to three effector molecules: IRE1, ATF6, and PERK. Cellular stress via the accumulation of unfolded
proteins can cause the disassociation of these effector molecules from GRP78, leading to the activation
of the UPR. One consequence is that PERK can phosphorylate eukaryotic translation initiation factor
2α, leading to the inhibition of cellular protein synthesis [64]. Our results showed GRP78 knockdown
did not lead to a substantial decrease in cellular protein synthesis and that the decrease in ZIKV protein
expression was specific to the virus. Whether the reduction in viral protein expression following
GRP78 depletion was because of a reduction in viral specific translation or rather because of increased
mis-folding and degradation on viral proteins has yet to be established. Additionally, two small
molecule inhibitors of GRP78, HNK and EGCG, had no effect on virus replication once viral RNA had
entered the cells. The anti-viral effect of EGCG was perhaps due to its ability to inhibit ZIKV virus
entry, as was suggested previously, or potentially by damaging and inactivating viral particles [49,50].
HNK and EGCG bind the ATPase domain of GRP78 and maintain its unfolded conformation [42],
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thereby inhibiting binding of unfolded substrates and activation of the UPR [48]. It has not been
determined if EGCG can interfere with the interaction between E and GRP78. The lack of a phenotype
following drug treatment may indicate that UPR pathways do not affect ZIKV infection in A549
cells. This is in contrast to some studies that have linked ZIKV infection to the induction of the UPR
in human fetal microcephalic cortices [29]. Here, the activation of the UPR is believed to impair
corticogenesis and neurogenesis, a phenotype that was reversed with the addition of UPR inhibitors.
Despite the difference in phenotype, it is worth noting that these observations were made in different
model systems.
We also showed that, in siN-treated ZIKV infected cells, host cell translation was significantly
reduced when compared to an uninfected control, a phenotype that has been reported for many viruses,
including some flaviviruses [65,66]. It is interesting to note that, despite reduced cellular translation,
GRP78 protein expression was maintained during ZIKV infection. Whether this was due to host stress
response or modulated by the virus still needs to be determined. The mechanism by which ZIKV
hijacks host translation has not yet been elucidated. Interestingly, in GRP78-depleted cells, we no longer
saw a reduction in host cell translation. This perhaps indicated that ZIKV requires GRP78 to modulate
host translation and could be the reason GRP78 depletion reduces ZIKV infection. The mechanism
behind this phenotype remains unclear but could be related to the organisation and the localisation
of viral replication factories. ZIKV replication factories are bound to ER membranes [14]. Similar to
other arthropod-transmitted flaviviruses, such as DENV, West Nile virus, and tick-borne encephalitis
virus [67–71], infection results in a complex redesign of the ER network. Such spatial organisation
would likely allow for coordination of metabolites required for RNA replication and close proximity to
the host cell’s translational machinery. Additionally, such complexes could protect viral RNA from
detection by cellular anti-viral RNA sensors. All flavivirus proteins, including structural proteins,
play a role in the formation of these structures [14,18,67–74]. dsRNA is formed at an intermediary
step of ZIKV replication and can be used as a marker for virus replication complexes [14]. In control
cells, ZIKV replication complexes clustered to a perinuclear locale as previously documented [14].
However, in GRP78 knockdown cells, dsRNA was more dispersed throughout the cell, indicating that
GRP78 could be needed for coordination of replication complexes to areas that can support efficient
viral protein synthesis, such as clustered to the ER. However, it is not yet clear how GRP78 can affect
translation of viral RNA or how localisation and compartmentalisation of replication factories affect
capturing of ribosomes and/or availability other resources.
It was proposed previously that GRP78 could represent a broad anti-viral target [75], as it has been
shown to be pro-viral for viruses beyond the flavivirus genus, including chikungunya virus, Ebola
virus, measles virus, influenza virus, hepatitis B virus, enterovirus, retroviruses, and coronaviruses
such as Middle East respiratory virus [75–84]. GRP78 is a multi-faceted protein with diverse roles
during viral life cycles; it has been shown to act as a (co-)receptor, to facilitate protein trafficking, and to
function as a chaperone. As such, GRP78 is a promising target for the development of anti-viral drugs.
The approach chosen highlights the strengths of proteomics approaches to understand virus–host
interactions. Our findings suggest that ZIKV should be added to the growing list of viruses that
depend on this important cellular factor, and the data show further roles for GFP78–E interactions
that go beyond a role in entry. Indeed, our findings suggest that flaviviruses E proteins may use
this cellular host factor in various ways, which points to broad and fundamental relevance of this
protein–protein interaction.
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